SI2978846T1 - Modificiran TGF-beta oligonukleotid za uporabo v postopku preprečevanja in/ali zdravljenja oftalmične bolezni - Google Patents
Modificiran TGF-beta oligonukleotid za uporabo v postopku preprečevanja in/ali zdravljenja oftalmične bolezniInfo
- Publication number
- SI2978846T1 SI2978846T1 SI201431537T SI201431537T SI2978846T1 SI 2978846 T1 SI2978846 T1 SI 2978846T1 SI 201431537 T SI201431537 T SI 201431537T SI 201431537 T SI201431537 T SI 201431537T SI 2978846 T1 SI2978846 T1 SI 2978846T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treating
- preventing
- ophthalmic disease
- modified tgf
- beta oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical class C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161474 | 2013-03-27 | ||
| EP13173078 | 2013-06-20 | ||
| EP13199831 | 2013-12-30 | ||
| EP13199826 | 2013-12-30 | ||
| EP13199838 | 2013-12-30 | ||
| PCT/EP2014/056222 WO2014154836A2 (en) | 2013-03-27 | 2014-03-27 | Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease |
| EP14715563.4A EP2978846B1 (en) | 2013-03-27 | 2014-03-27 | Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2978846T1 true SI2978846T1 (sl) | 2020-07-31 |
Family
ID=50440642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201431537T SI2978846T1 (sl) | 2013-03-27 | 2014-03-27 | Modificiran TGF-beta oligonukleotid za uporabo v postopku preprečevanja in/ali zdravljenja oftalmične bolezni |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9688988B2 (sl) |
| EP (1) | EP2978846B1 (sl) |
| JP (1) | JP6475226B2 (sl) |
| KR (1) | KR102094572B1 (sl) |
| CN (1) | CN105283551B (sl) |
| BR (1) | BR112015024760B8 (sl) |
| CA (1) | CA2908101C (sl) |
| DK (1) | DK2978846T3 (sl) |
| EA (1) | EA201591594A1 (sl) |
| ES (1) | ES2784213T3 (sl) |
| HU (1) | HUE049246T2 (sl) |
| LT (1) | LT2978846T (sl) |
| PL (1) | PL2978846T4 (sl) |
| PT (1) | PT2978846T (sl) |
| SI (1) | SI2978846T1 (sl) |
| SM (1) | SMT202000175T1 (sl) |
| WO (1) | WO2014154836A2 (sl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018009895A1 (en) * | 2016-07-08 | 2018-01-11 | Autotelic Llc | Methods for trabedersen dosing by auc |
| US11207341B2 (en) | 2016-11-11 | 2021-12-28 | Isarna Therapeutics Gmbh | TGF-beta oligonucleotide for use in treatment of ophthalmic diseases |
| US11771703B2 (en) | 2017-03-17 | 2023-10-03 | The Johns Hopkins University | Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression |
| CN113018508A (zh) * | 2021-03-15 | 2021-06-25 | 西安交通大学医学院第一附属医院 | 一种表面修饰的人工晶状体及其制备方法 |
| KR102549208B1 (ko) * | 2021-04-08 | 2023-06-30 | 연세대학교 산학협력단 | 심혈관 질환과 관련된 LncRNA 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE211762T1 (de) | 1993-04-30 | 2002-01-15 | Biognostik Ges | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) |
| EP1160319A3 (en) | 1993-04-30 | 2002-03-06 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta) |
| US20040006030A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
| EP1568383A3 (en) | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
| CA2558667A1 (en) * | 2004-02-27 | 2005-09-15 | Antisense Pharma Gmbh | Antisense oligonucleotides for inhibiting the formation of metastases in cancer |
| EP1935428A1 (en) | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
| EP2580326A1 (en) * | 2010-06-11 | 2013-04-17 | Antisense Pharma GmbH | Method for selective oligonucleotide modification |
| EP2453017A1 (en) | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
| JP2015518713A (ja) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Ｕｔｒｎ発現を調節するための組成物及び方法 |
-
2014
- 2014-03-27 HU HUE14715563A patent/HUE049246T2/hu unknown
- 2014-03-27 CA CA2908101A patent/CA2908101C/en active Active
- 2014-03-27 BR BR112015024760A patent/BR112015024760B8/pt active IP Right Grant
- 2014-03-27 US US14/779,930 patent/US9688988B2/en active Active
- 2014-03-27 KR KR1020157030781A patent/KR102094572B1/ko active Active
- 2014-03-27 JP JP2016504683A patent/JP6475226B2/ja active Active
- 2014-03-27 SM SM20200175T patent/SMT202000175T1/it unknown
- 2014-03-27 DK DK14715563.4T patent/DK2978846T3/da active
- 2014-03-27 EP EP14715563.4A patent/EP2978846B1/en active Active
- 2014-03-27 PL PL14715563T patent/PL2978846T4/pl unknown
- 2014-03-27 LT LTEP14715563.4T patent/LT2978846T/lt unknown
- 2014-03-27 CN CN201480030396.2A patent/CN105283551B/zh active Active
- 2014-03-27 SI SI201431537T patent/SI2978846T1/sl unknown
- 2014-03-27 ES ES14715563T patent/ES2784213T3/es active Active
- 2014-03-27 PT PT147155634T patent/PT2978846T/pt unknown
- 2014-03-27 WO PCT/EP2014/056222 patent/WO2014154836A2/en not_active Ceased
- 2014-03-27 EA EA201591594A patent/EA201591594A1/ru unknown
-
2017
- 2017-05-12 US US15/593,764 patent/US10125368B2/en active Active
-
2018
- 2018-11-09 US US16/185,822 patent/US20190144865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2908101A1 (en) | 2014-10-02 |
| JP6475226B2 (ja) | 2019-02-27 |
| JP2016519573A (ja) | 2016-07-07 |
| US10125368B2 (en) | 2018-11-13 |
| BR112015024760B1 (pt) | 2021-09-21 |
| SMT202000175T1 (it) | 2020-05-08 |
| EP2978846B1 (en) | 2019-12-25 |
| KR102094572B1 (ko) | 2020-03-30 |
| BR112015024760B8 (pt) | 2022-06-21 |
| CA2908101C (en) | 2021-06-22 |
| ES2784213T3 (es) | 2020-09-23 |
| WO2014154836A3 (en) | 2014-11-20 |
| CN105283551B (zh) | 2018-11-06 |
| PT2978846T (pt) | 2020-04-21 |
| LT2978846T (lt) | 2020-04-10 |
| BR112015024760A2 (pt) | 2017-10-24 |
| US20190144865A1 (en) | 2019-05-16 |
| PL2978846T3 (pl) | 2020-09-21 |
| EA201591594A1 (ru) | 2016-05-31 |
| PL2978846T4 (pl) | 2020-09-21 |
| HK1221254A1 (en) | 2017-05-26 |
| WO2014154836A2 (en) | 2014-10-02 |
| EP2978846A2 (en) | 2016-02-03 |
| US20160040167A1 (en) | 2016-02-11 |
| US20170314025A1 (en) | 2017-11-02 |
| CN105283551A (zh) | 2016-01-27 |
| US9688988B2 (en) | 2017-06-27 |
| KR20150140702A (ko) | 2015-12-16 |
| DK2978846T3 (da) | 2020-04-06 |
| HUE049246T2 (hu) | 2020-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278018A (en) | Methods for the treatment or prevention of ophthalmological conditions | |
| PT2991600T (pt) | Micro-oclusões e métodos relacionados para o tratamento da pele | |
| ZA201506216B (en) | Phototherapeutic device, method and use | |
| PT2897536T (pt) | Dispositivo para tratamento da oclusão vascular | |
| EP2895120A4 (en) | SYSTEMS AND METHOD FOR HAPTIC STIMULATION | |
| ZA201507514B (en) | Method for non-toxic treatment for drug withdrawal | |
| EP3079766A4 (en) | Meditation treatment device and method | |
| IL245183A0 (en) | Methods for the treatment and prevention of an implant against surrogate disease | |
| EP2967687A4 (en) | METHODS AND IMPLANTS FOR TREATING HAMMER ORTEIL AND OTHER DEFORMITIES | |
| IL269825A (en) | Method and device for tissue approximation | |
| IL246537A0 (en) | Apparatus and method for treating sleep apnea | |
| GB2579726B (en) | Device and method for less forceful tissue puncture | |
| GB2512147B (en) | Device and method for treating vascular dissections | |
| EP2933234A4 (en) | PROCESS FOR REMOVING HEAVY METAL AND DEVICE FOR REMOVING HEAVY METAL | |
| LT2978846T (lt) | Modifikuotas tgf-beta oligonukleotidas, skirtas panaudoti akių ligų prevencijos ir (arba) gydymo būdui | |
| SG11201405559TA (en) | Component and method for treating viral disease | |
| IL252904A0 (en) | Methods and factors for treating diseases | |
| IL246286A0 (en) | A medical preparation for the prevention and treatment of advanced myopia. | |
| EP3069726A4 (en) | Agent and method for treating autoimmune disease | |
| EP3027111A4 (en) | Nanoparticle diagnostic and methods for treating disease | |
| EP2927332A4 (en) | NEUTRALIZATION PROCESSING METHOD AND NEUTRALIZING AGENT | |
| PL2844313T3 (pl) | Urządzenie do przeprowadzania sposobu konserwacji urządzenia do obróbki krwi oraz sposób konserwacji urządzenia do obróbki krwi | |
| GB201410954D0 (en) | Skin treatment devices and methods | |
| PL2947982T3 (pl) | Sposób i system do zabiegów na zwierzęciu do wykonywania czynności dotyczącej zwierzęcia na części zwierzęcia w przestrzeni zwierzęcia | |
| ZA201302565B (en) | Methods for treating hyperuricemia and related diseases |